Advertisement
Advertisement
U.S. markets close in 2 hours 5 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Burning Rock Biotech Limited (BNR)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.5400-0.1300 (-3.54%)
As of 01:54PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close3.6700
Open3.6000
Bid3.5400 x 1000
Ask3.5600 x 800
Day's Range3.4900 - 3.6100
52 Week Range1.7400 - 22.2200
Volume118,805
Avg. Volume795,148
Market Cap372.366M
Beta (5Y Monthly)-0.37
PE Ratio (TTM)N/A
EPS (TTM)-1.2680
Earnings DateAug 31, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.11
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for BNR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Burning Rock Biotech Limited
    Analyst Report: I-MabI-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in late 2023 or early 2024. Core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor; uliledlimab, a potential best-in-class CD73 inhibitor; and eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature.
    Rating
    Fair Value
    Economic Moat
    yesterdayMorningstar
View more
Advertisement
Advertisement